LRP8 is a receptor for tick-borne encephalitis virus

We thank K. Paez, E. Valencia and M. Ramirez, K. Dempsey, C. O'Brien, A. I. Kuehne and N. M. Josleyn for laboratory management and technical assistance; K. Cogliano for programmatic and administrative support; K. Stiasny for providing TBEV monoclonal antibodies B2 and B4; the members of the Einstein Epigenomics Core and Computational Genomics Core for NGS analysis and data analysis support; the staff at the Einstein Flow Cytometry Core Facility (supported by the Einstein National Cancer Institute's cancer center support grant P30CA013330) for surface flow cytometry sorting of cell lines; the members of the Einstein Macromolecular Therapeutics Development Facility for protein characterization by size-exclusion chromatography; and the staff at the Karolinska Institutet ANA Futura BSL3 Core Facility (supported by the Infrastructure Board at Karolinska Institutet) for enabling virus studies under high-containment. US National Institutes of Health grant R01AI132633 (K.C.); Marianne and Marcus Wallenberg Foundation (S.G.-R.); Region Stockholm (Clinical Research Appointment) (S.G.-R.); Swedish Research Council (Dnr 2020-06249 and 2021-06602) (S.G.-R.); Swedish Research Council (Dnr 2020-06224) (A.K.O.); US National Institute of Allergy and Infectious Diseases grants R01AI165932 and R01AI174584 (B.M.); Congressionally Directed Medical Research Programs grant HT9425-24-1-0873 (C.F.); US National Institute of Allergy and Infectious Diseases grant R21AI182834 (C.K.M.); and French National Research Agency grants ANR-18-CE92-0006, ANR-22-CE35-0004 and ANR-10-LABX-62-10 IBEID (F.A.R.). Opinions, conclusions, interpretations and recommendations are those of the authors and are not necessarily endorsed by the US Department of the Army, the US Department of Defense or the US Department of Health and Human Services.